Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Evotec SENASDAQ: EVO

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 355.12M shares rose 0.0% year over year, in line with the +0.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.1% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +0.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
355.12M-0.1% QoQ
Last fiscal yearDec 2025
355.16M+0.2% YoY
LTMMar 2026
355.28M+0.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+0.2%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
355.16M EUR
Year-over-year change
+0.2%
4-year CAGR
+1.6%

Weighted Avg Shares (Diluted) vs competitors

How EVO compares with its peers on the latest reported figures

  • EVO's LTM Mar 2026 weighted avg shares (diluted) of 355.28M shares is the highest of the 11 companies compared; the peer median is 90.61M shares.
  • Its year-over-year change of +0.1% is the 9th highest of 11, against a peer median of +4.7%.
  • Over three fiscal years its annual growth of +0.2% compares with a peer median of +6.6%.
EVO Competitors Peer median
Weighted Avg Shares (Diluted) for EVO and competitors
Company Period LTM YoY 3-year CAGR
EVOEvotec SELTM Mar 2026355.28M +0.1%+0.2%
ALVOAlvotechLTM Mar 2026305.77M +6.0%+12.2%
TDOCTeladoc Health, Inc.LTM Mar 2026176.73M +2.7%+3.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026146.1M +155.9%+166.8%
NVCRNovoCure LimitedLTM Mar 2026112.28M +3.5%+2.1%
TLRYTilray Brands, Inc.LTM Feb 2026106.71M +24.0%+22.8%
SDGRSchrödinger, Inc.LTM Sep 202674.52M +1.8%+1.1%
PHVSPharvaris N.V.LTM Sep 202665.72M +16.6%+20.8%
AZTAAzenta, Inc.LTM Sep 202645.19M -1.3%-12.0%
PCRXPacira BioSciences, Inc.LTM Mar 202643.45M -9.6%-1.1%
HROWHarrow Health, Inc.LTM Mar 202637.93M +6.1%+10.2%
Peer median (excluding EVO) 90.61M+4.7%+6.6%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue618.03M751.45M781.43M796.97M757.26M
Cost of Revenue466.49M577.38M606.38M682.09M694.6M
Gross Profit151.54M174.07M175.05M114.88M62.66M
Gross Margin24.5%23.2%22.4%14.4%8.3%
Research & Development65.7M76.64M68.53M50.86M74.33M
Selling, General & Admin105.45M156.19M169.61M188.2M123.65M
Operating Expenses110.55M153.22M222.56M257.4M197.97M
Depreciation & Amortization70.4M83.2M92.98M101.62M95.55M
EBITDA316.63M(57.61M)24.13M(80.66M)(13.89M)
EBITDA Margin51.2%-7.7%3.1%-10.1%-1.8%
Operating Income41M20.85M(47.51M)(142.52M)(135.31M)
Operating Margin6.6%2.8%-6.1%-17.9%-17.9%
Interest Income2.27M8.34M9.26M2.44M4.25M
Interest Expense9.25M13.15M11.74M11.7M13.87M
Other Income / Expenses195.98M(174.81M)(33.09M)(51.46M)12M
Income Before Tax236.98M(153.96M)(80.59M)(193.98M)(123.31M)
Pre-Tax Margin38.3%-20.5%-10.3%-24.3%-16.3%
Income Tax Expense21.47M21.7M3.32M2.1M(23.88M)
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Net Margin34.9%-23.4%-10.7%-24.6%-13.1%
EPS (Basic)0.65(0.49)(0.23)(0.56)(0.28)
EPS (Diluted)0.65(0.49)(0.23)(0.56)(0.28)
Weighted Avg Shares332.81M353.35M353.87M353.29M355.16M
Weighted Avg Shares (Diluted)332.81M353.41M353.87M354.59M355.16M

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.